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α/β or TD50 in normal tissue by immunological aspects was 
expected to improve normal tissue response in radiotherapy. 
For more precise prediction of such optimal protocols, 
treatment planning systems should be incorporated the 
biological optimization in clinical practice. 
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The Italian Center for Oncologic Hadrontherapy is up to date 
in the fifth year of its clinical activity. The total number of 
patients treated is 685 (up to November 2015). The 
treatments with carbon ions are about three times those with 
protons. An important part of treatments with carbon ions is 
directed on sarcomas, bones and soft tissue sarcomas, 
salivary glands tumours. In the table, treated patients are 
listed according to the clinical trials approved by the Italian 
Ministry of Health.  
Another substantial part of treatments regards re-irradiation 
of several pathologies, especially head and neck re-
treatments of several tumours. 
An important goal reached in the last year is the treatment 
of moving targets. Pancreatic adenocarcinomas, hepatocellar 
carcinomas and pathologies located in moving sites are 
treated through the vertical beam line with gating and 
rescanning technology. 
Treated volumes’ issue has been discussed. Many pelvic 
sarcomas and chordomas cases refer to hadrontherapy 
treatment when already reached remarkable volumes. These 
cases are subject of discussion amongst radiation oncologists 
and medical physicists. The parameters taken in 
consideration are PTV (Planning Treatment Volume) and GTV 
(Gross Tumour Volume). They are statistically evaluated to 
elaborate the best treatment strategy in term of dose and 
planning option. This issue has also economic implications. 
The treatment of major tumour volumes using mostly more 
than one field occupies the treatment room for a period of 
time equal, when not superior, to two or more patients. The 
next challenge is to improve all steps to give such treatments 
in less time. 
Most of the patients treated at CNAO are referred from 
Italian Cancer institutes but an increasing number of EU 
patients comes to Pavia through international agreements. 
In the coming period CNAO is expected to receive the 
authorization to treat all the clinical case worth to receive 
hadrontherapy treatment.  
Clinical study description Particle
Total 
number 
of 
patients 
treated
Proton radiation therapy for chordomas and chondrosarcomas of the 
skull base Protons 52
Proton therapy of spine chordoma and chondrosarcoma (amended) Protons 16
Proton therapy of intracranial meningioma Protons 24
Proton therapy of brain tumors Protons 11
Proton therapy of recurrent cervico-cephalic area tumors Protons 21
Proton boost for locally advanced cervico-cephalic area tumors Protons 28
Proton therapy of glioblastoma Protons 1
Proton re-irradiation of recurrent spine  chordoma and Protons 6
Carbon ion therapy of  adenoid cystic carcinoma of salivary glands Carbon ions 106
Carbon ion re-irradiation of recurrent pleomorphic adenomas Carbon ions 19
Carbon ion re-irradiation of recurrent rectal cancer Carbon ions 8
Carbon ion radiotherapy for bone and soft tissue sarcoma of cervico-
cephalic area Carbon ions 94
Carbon ion radiotherapy for bone and soft tissue sarcoma of trunk Carbon ions 119
Carbon ion  therapy of recurrent cervico-cephalic area tumors Carbon ions 90
Carbon ion therapy of malignant melanoma of the mucous of the 
upper aerodigestive tract Carbon ions 14
Carbon ion therapy for high risk prostate cancer Carbon ions 9
Carbon ion therapy of primary and secondary orbital tumors Carbon ions 13
Carbon ion therapy for pancreatic cancers Carbon ions 11
Carbon ions therapy of primary malignant tumors of the liver Carbon ions 4
Carbon ion re-irradiation of recurrent spinal chordoma and Carbon ions 7
Protons and/or carbon ion integrated radiotherapy for poor prognosis 
in patients with inoperable sinonasal tumor
Protons/ Carbon 
ions 4
Other - 28
685  
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Molecular imaging provides unique information on the tumor 
phenotype (i.e. tumor cells and tumor microenvironment), 
influencing treatment decisions and adaptation of therapy by 
early prediction of treatment outcome. With the increasing 
importance of systemic targeted therapies and of high 
precision external beam radiotherapy, interrogating tumor 
characteristics before and during therapy becomes 
increasingly important. 
Key features like tumor metabolism, proliferation and 
protein synthesis can be depicted by the well-known 
radiopharmaceuticals FDG, FLT and e.g. FAZA, respectively. 
Furthermore, imaging receptor expression on tumor cells 
with e.g. radiolabeled antibodies and peptides can provide 
information on the presence, heterogeneity, accessibility, 
and modulation of these receptors for targeted therapies. 
Thirdly, small molecules like TKI may radiolabeled providing 
similar insight in tumor pathophysiology allowing better 
selection of patients likely to respond to treatment. A 
distinct form of theranostics utilizes targeting molecules, 
radiolabeled with an gamma or positron emission for imaging 
selecting patients for treatment with the same molecule, 
now radiolabeled with a beta-emitter. 
In conclusion, various applications of theranostics provide 
crucial insight in tumor biology, the choice and adaptation of 
treatment, allowing better selection of treatment to achieve 
better outcomes for cancer patients.  
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The aim of the study was to investigate the biological effects 
in human lymphocytes irradiated with the 60 MeV proton 
beam in the Bronowice Cyclotron Center IFJ PAN. The 
relative biological effectiveness (RBE) of the proton beam in 
comparison to X-ray’s was estimated by the comet method. 
Whole blood samples were collected from 5 healthy donors. 
For dose-response studies lymphocytes were used submerged 
in agarose on microscopic slides, set in a specially designed 
PMMA phantom located at the isocenter. Cells were irradiated 
in Eppendorf vessels located in the mead of Spread-Out Bragg 
Peak (SOBP) in the fully modulated proton beam with range 
of 29 mm. 
For reference, the lymphocytes were exposed to the 250 kV 
X-rays. For both sources of radiations, dose-effect curves at a 
dose range (0-4Gy) were estimated. The level of DNA damage 
was assessed using the alkaline version of comet assay, also 
called the DNA single cell gel electrophoresis (SCGE). 
The obtained dose-response relationships for the level of DNA 
damage showed linear character for both sources of radiation 
(R2 = 0.994 for protons and R2 = 0.995 for X-rays). The 
efficiency of protons in inducing DNA strand breaks for the 
dose range from 0.3 to 4 Gy calculated as the ratio of the 
two α coefficients was 1.37. The average RBE calculated 
from the proton and X-ray dose required for the iso-effective 
TDNA comet assay parameter was 1.51 + / - 0.05 (range 1.45-
1.66).  
This observation suggests that the standard alkaline comet 
assay is reliable technique for estimation of DNA damage 
caused by proton and X-ray radiation in vitro. 
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Presently for production of medical radionuclides the 
cyclotrons are widely used which are very safe and reliable 
installations. At PNPI a high current cyclotron C-80 with the 
energy of extracted proton beam of 40-80 MeV and the 
current up to 200 μA has been constructed. One of the main 
goals of C-80 is production of a wide spectrum of medical 
radio-nuclides for diagnostics and therapy. At the beam of C-
80 the project of radioisotope complex RIC-80 (Radio Isotopes 
at the cyclotron C-80) has been worked out. In the presented 
submission the project of RIC-80 complex is discussed, which 
includes three target stations for production of radio-nuclides 
for medicine. The peculiarity of the proposed radio-isotope 
facility is the use of the mass-separator with the target-ion 
source device as one of the target stations for on-line, or 
semi on-line production of a high purity separated radio-
nuclides. The results on the target development for 
production of radio-isotope generator for PET diagnostics 82Sr 
are presented. 
 
Keywords: Radioisotopes for medicine, mass-separator, 
targets for radioisotope production 
 
 
 
167 
Fused Toes Homolog (FTS) regulates EGF-induced 
epithelial–mesenchymal transition (EMT) and migration of 
cervical cancer cells 
W. Park1, S. Muthusami1, D.S. Prabakaran1and J. Yu2 
1Department of Radiation Oncology, Chungbuk National 
University College of Medicine, Cheongju, 361-763, Republic 
of Korea 
2Department of Environmental and Tropical Medicine, Konkuk 
University College of Medicine, Chungju, 380-701, Republic of 
Korea  
 
Purpose: Epithelial–mesenchymal transition (EMT) allows 
tumor cells to acquire the capacity to infiltrate surrounding 
tissue and to ultimately metastasize to distant sites. Limited 
information is available on the regulation of EMT in cervical 
cancer. Epidermal growth factor (EGF) has beenreported as a 
potent stimulator of cervical cancer invasiveness. 
Upregulation of epidermal growth factor receptor (EGFR) 
expression is reported in the recurrent cervical cancer. Fused 
Toes Homolog (FTS) has been reported as a general regulator 
of AKT activity in the control of differentiation, proliferation, 
and apoptosis in many cell types. Importantly, studies from 
our laboratory have shown overexpression of FTS in cervical 
cancer specimens and the expression of this protein increases 
with advancement of the disease. Hence, we studied the role 
of FTS in EGF-induced EMT in cervical cancer cells. 
Materials and Methods: A human cervical carcinoma cell line 
ME180 was used. Gene silencing was obtained using siRNA. 
Protein expression was studied by Western blot and 
immunofluorescence. Cell migration and invasion was 
assessed by wound healing and matrigel migration assay.  
Results: EGF treatment induced the change of EMT markers 
and increased cell migration. EGF treatment also increased 
phosphorylated EGFR and ERK and nuclear level of ATF-2. 
The binding of ATF-2 to the promoter region of FTS was 
evidenced after EGF treatment. Pretreatment with PD98059 
and gefitinib prevented EGF-induced FTS expression. FTS-
silencing reduced EMT and cell migration by EGF treatment. 
Conclusions: These results suggest that upregulation of FTS 
by EGF is mediated via EGF/EGFR/ERK/ATF-2 and this 
facilitates EGF-mediated EMT process in cervical cancer 
cells. FTS can be a potential target to circumvent cervical 
cancer progression driven by EGF. 
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Purpose: In PET-based treatment verification the low 
counting statistics PET data acquired during/after the 
treatment (Measured PET) must be compared to a Monte 
Carlo estimate of the β+ distribution induced by the 
treatment (Expected PET) based on the planning Computed 
Tomography (CT) images [1]. Given the extremely low quality 
of Measured PET images and the consequent difficulties in 
mismatch estimation, we proposed to use a 4D Maximum 
Likelihood (ML) reconstruction strategy considering Expected 
PET and Measured PET as two frames of a 4D dataset and 
providing an estimate of the motion field mapping one frame 
to the other [2]. 
The aim of this work is to optimize the strategy on a 
